

CURRICULUM VITAE
REGINALD Y. GOHH, M.D.

PERSONAL INFORMATION

Date of Birth: January 20, 1964
Place of Birth: Manila, Philippines
Citizenship: US
Business Address: Rhode Island Hospital
593 Eddy Street
Providence, RI 02903
Business Telephone: (401)444-8345
Business Fax: (401)444-3283
Electronic Mail Address: Rgohh@Lifespan.org

EDUCATION

Undergraduate University of Toronto
Biological Sciences, B. S. (1985)
Graduated with Distinction
Medical School Meharry Medical College, 1986-1990
M.D. (1990), Graduated with Honors
Other Advanced Degrees Brown University
M.A. (2006), Ad Eundum

POSTGRADUATE TRAINING

Residency: Rhode Island Hospital/Brown University
Providence, Rhode Island
Categorical Internal Medicine, 1990-1993
Fellowship: Rhode Island Hospital/Brown University
Providence, Rhode Island
Nephrology Fellowship, 1993-1995
New England Deaconess Hospital/Harvard University
Boston, Massachusetts
Transplant Nephrology Fellowship, 1995-1996

POSTGRADUATE HONORS AND AWARDS

Alpha Omega Alpha, 1990
Meharry Medical College
Nashville, Tennessee
Young Investigator's Award
American Society of Transplant Physicians
Dean's Teaching Excellence Award, 2003, 2004
Brown University School of Medicine
Best Doctors in America, 2009-2012

Beckwith Family Award for Outstanding Teaching, 2010
Dept. of Medicine, Alpert Medical School of Brown University

Top Doctor, 2011
Rhode Island Monthly

Attending Teaching Award, 2012
Dept. of Medicine, Alpert Medical School of Brown University

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

American Board of Internal Medicine, 1993, 2003
Rhode Island State Medical License (#8764), 1994
American Board of Internal Medicine, Nephrology Subspecialty, 1996,
2006

ACADEMIC APPOINTMENTS

Medical Director, Division of Organ Transplantation, 1995-
Rhode Island Hospital
Providence, RI

Assistant Professor of Medicine, 1996- 2005
Warren Alpert School of Medicine of Brown University
Providence, RI

Associate Professor of Medicine, 2005-
Warren Alpert School of Medicine of Brown University
Providence, RI

HOSPITAL APPOINTMENTS

Staff Nephrologist, 1995-
Rhode Island Hospital
Providence, RI

Courtesy Staff Physician, 1996-
Miriam Hospital
Providence, RI

On-Station Contract Nephrologist, 1996-
Veteran's Administration Medical Center
Providence, RI

Medical Staff, Artificial Kidney Centers of RI, 2002-
Providence, RI

Provisional Medical Staff, 2009
Kent Hospital
Warwick, RI

OTHER APPOINTMENTS

Editorial Board, *Transplantation*
1998-

Reviewer, *American Journal of Transplantation*
2003-

Reviewer, *Kidney International*
2005-

Reviewer, *Obstetric Medicine*
2009-

Reviewer, *Journal of Diabetes and its Complications*
2010-

HOSPITAL COMMITTEES

Procedure Review Committee, 2002-
Rhode Island Hospital
Providence, RI

UNIVERSITY COMMITTEES

Search Committee, Transplant Surgeon, 2012
Warren Alpert School of Medicine of Brown University

MEMBERSHIP IN SOCIETIES

ESRD Network of New England
Board of Directors and Chairman of Transplant Committee,
1996-2000

Coalition of Donation/RI Organ Donor Awareness Committee
Board of Directors, 1997-2000, 2007- present

American Society of Internal Medicine/ American College of
Physicians
Rhode Island Chapter Council, 1997-2000

American Society of Nephrology, 1988-

National Kidney Foundation
Regional Board of Directors of MA and RI, 1998-2003
Medical Advisory Board, 1998-2000

International Society of Nephrology, 1999-

American Society of Transplantation, 2001-

PUBLICATIONS

Hsieh F, **Gohh RY**, Dworkin LD. Acute renal failure and the MELAS syndrome, a mitochondrial encephalomyopathy. *J Am Soc Nephrol* 1996; 7: 647-652.

Gohh RY, Williams ME, Crosson AW, Federman M, Zambetti FX. Late renal allograft failure secondary to thrombotic microangiopathy associated with disseminated malignancy. *Am J Nephrol* 1997; 17: 176-180.

Morrissey PE, **Gohh R**, Shaffer D, Crosson A, Madras PN, Sayhoun AI, Monaco AP. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or CyA toxicity with pathologic staging by the Banff criteria. *Transplantation* 1997; 63: 845-848.

Bostom AG, **Gohh RY**, Tsai MY, Hopkins-Garcia BJ, Nadeau MS, Bianchi L, Jacques PF, Rosenberg IH, Selhub J. Excess prevalence of fasting and post-methionine loading hyperhomocysteinemia in stable renal transplant recipients. *Atheroscl Thromb Vasc Biol* 1997; 1.

Bostom AG, Shemin DG, **Gohh RY**, Tsai MY, Hopkins-Garcia BJ, Nadeau MS, Bianchi L, Jacques PF, Rosenberg IH, Selhub J. Lower fasting total plasma homocysteine levels in stable renal transplant recipients versus maintenance hemodialysis patients. *Transplant Proc* 1998; 30: 160-162.

Bostom AG, **Gohh RY**, Beaulieu A, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg IH. Brief Communication: Treatment of hyperhomocysteinemia in renal transplant recipients: a randomized, placebo-controlled trial. *Ann Int Med* 1997; 127: 1089-1092.

Morrissey PE, **Gohh RY**, Madras PN, Shaffer D, Davis C, Conway P, Sahyoun A, Monaco AP. Etiology of early renal allograft dysfunction after live donor renal transplantation. *Transplant Proc* 1998; 30.

Morrissey P, **Gohh R**, Madras P, Monaco AP. Pulmonary fibrosis secondary to administration of mycophenolate mofetil [letter]. *Transplantation* 1998; 1414.

Bostom AG, **Gohh RY**, Bausserman L, Hakas D, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Serum cystatin C as a determinant of fasting total homocysteine levels in renal transplant recipients with a normal serum creatinine. *J Am Soc Nephrol* 1999; 10: 164-166.

Bostom AG, **Gohh RY**, Liagaudas G, Beaulieu AJ, Han H, Jacques PF, Dworkin L, Rosenberg IH, Selhub J. Prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease after fortification of cereal grain flour with folic acid. *Atherosclerosis* 1999; 145: 221-224.

Beaulieu AJ, Lapane KL, **Gohh RY**, Selhub J, Monaco AP, Dworkin LD, Rosenberg IH, Bostom AG. Short-term reproducibility of total homocysteine determinations in stable renal transplant patients. *Transplant Proc* 1999; 31: 2121-2123.

Bostom AG, **Gohh RY**, Beaulieu AJ, Han H, Jacques PF, Selhub J, Dworkin L, Rosenberg IH. Determinants of fasting plasma total homocysteine levels among stable renal transplant recipients in the era of folic acid fortified cereal grain flour. *Transplantation* 1999; 68: 257-261.

Bostom AG, Shemin D, **Gohh RY**, Beaulieu AJ, Jacques PF, Dworkin L, Selhub, J. Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients. *Transplantation* 2000; 69(10): 2128-2131.

Beaulieu AJ, **Gohh RY**, Han HW, Hakas D, Jacques PF, Selhub J, Bostom AG. Enhanced reduction of fasting total homocysteine levels with supraphysiological versus standard multivitamin dose folic acid supplementation in renal transplant recipients. *Arterioscl Thromb Vasc Bio* 2000; 19(12): 2918-2921.

Kerr P, **Gohh R**, Robinson-Bostom L. Cutaneous Epstein-Barr virus-induced post-transplantation lymphoproliferative disorder. *Pathology* 2000; 27(10): 543.

Gohh RY, Morrissey PE, Madras PN, Monaco AP. Controversies in organ donation: The altruistic living donor. *Nephrol Dial Transplant* 2001; 16(3): 619-621.

Bostom AG, Kronenberg F, **Gohh RY**, Schwenger V, Ritz E, Selhub J. Chronic renal transplantation: a model for hyperhomocysteinemia in renal insufficiency. *Atherosclerosis* 2001; 156(1): 227-230.

Ramirez P, **Gohh R**, Kestin A, Monaco A, Morrissey P. Renal allograft loss due to proximal extension of ileofemoral deep venous thrombosis. *Clin Transplant* 2002; 16(4): 310-313.

Yango A, Morrissey P, Monaco A, Butera B, **Gohh RY**. Successful treatment of tacrolimus-associated thrombotic microangiopathy with sirolimus conversion and plasma exchange. *Clin Nephrol* 2002; 58(1): 77-78.

Morrissey P, **Gohh R**, Monaco A. A novel scale of immunosuppression exposure and correlation to outcomes after renal transplantation. *Transplant Proc* 2002; 34(5): 1640.

Morrissey PE, Ramirez PJ, **Gohh RY**, Yango AF, Kestin A, Madras PN, Monaco AP. Management of thrombophilia in renal transplant patients. *Am J Transplant* 2002; 2(9): 872-876.

Yango A, Morrissey P, **Gohh R**, Wahbeh A, Monaco A. Donor-transmitted parvovirus infection in a kidney transplant recipient presenting as pancytopenia and allograft dysfunction. *Transpl Infect Dis* 2002; 4(3): 163-166.

Yango A, Morrissey P, Monaco A, **Gohh R**, Centracchio J, Dworkin L. Renal production of hepatocyte growth factor increases after unilateral nephrectomy in man. *Transplant Proc* 2002; 34(8): 3128-9.

Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, Monaco A, **Gohh R**. Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. *Nephrol Dial Transplant* 2003 Apr; 18(4): 809-13.

Urbina BY, **Gohh R**, Fischer SA. Oerskovia xanthineolytica endocarditis in a renal transplant patient: case report and review of the literature. *Transplant Infect Dis* 2003; 5: 195-198.

Morrissey PE, **Gohh R**, Yango A, Gautam A, Monaco AP. Renal transplant survival from older donors: a single center experience. *Arch Surg*. 2004 Apr;139(4):384-9; discussion 389.

Mendonza A, Akhlaghi F, **Gohh R**. Determination of cyclosporine in saliva using liquid chromatography-tandem mass spectrometry. *Ther Drug Monit*. 2004 Oct;26(5):569-575.

Morrissey PE, Reinert S, **Gohh R**, Yango A, Gautam A, Monaco AP. Factors contributing to acute rejection in renal transplantation: the role of noncompliance. *Transplant Proc* 2005 Jun;37(5):2044-7.

Tran MQ, **Gohh RY**, Morrissey PE, Dworkin LD, Gautam A, Monaco AP, Yango AF. Cryptosporidium infection in renal transplant patients. *Clin Neph* 2005 April; 63(4): 305-309.

Gohh RY, Yango AF, Morrissey PE, Monaco AP, Gautam AG, Sharma M, McCarthy ET, Savin, VJ. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. *Am J Transplant* 2005 Dec; 5(12): 2907-2912.

Gautam A, Morrissey PE, **Gohh R**, Yango A, Monaco AP. Experience with sirolimus for calcineurin minimization/elimination in pancreas-after-kidney transplantation. *Transplant Proc*. 2005 Oct;37(8):3542-3

Morrissey PE, Dube C, **Gohh R**, Yango A, Gautam A, Monaco AP. Good samaritan kidney donation. *Transplantation*. 2005 Nov 27;80(10):1369-73.

Akhlaghi F, Patel CG, Zuniga XP, Halilovic J, Preis IS, **Gohh RY**. Pharmacokinetics of Mycophenolic Acid and Metabolites in Diabetic Kidney Transplant Recipients. *Ther Drug Monit*. 2006 Feb;28(1):95-101.

Grossberg JA, Reinert SE, Monaco AP, **Gohh R**, Morrissey PE. Utility of a mathematical nomogram to predict delayed graft function: a single center experience. *Transplantation*. 2006 Jan 27;81(2):155-9.

Yango AF, **Gohh RY**, Monaco AP, Reinert SE, Gautam A, Dworkin LD, Morrissey PE. Excess risk of renal allograft loss and early mortality among elderly recipients is associated with poor exercise capacity. *Clin Nephrol* 2006 Jun; 65 (6); 401-7..

Mendonza AE, **Gohh RY**, Akhlaghi F. Analysis of Mycophenolic acid in saliva using liquid chromatography tandem mass spectrometry. *Ther Drug Monit* 2006; 28: 402-406.

Gautam A, Morrissey PE, Brem AS, Fischer SA, **Gohh RY**, Yango AF, Monaco AP. Use of an immune function assay to monitor immunosuppression for treatment of post-transplant lymphoproliferative disorder. *Pediatr Transplant*. 2006 Aug;10(5):613-6.

Gohh RY, Waren G. The preoperative evaluation of the transplanted patient for nontransplant surgery. *Surg Clin N Am*. 2006

Gautam A, Fischer SA, Yango AF, **Gohh RY**, Morrissey PE, Monaco AP. Cell mediated immunity (CMI) and post transplant viral infections - Role of a functional immune assay to titrate immunosuppression. *Int Immunopharmacol*. 2006 Dec 20;6(13-14):2023-6.

Campbell RM, Ney A, **Gohh R**, Robinson-Bostom L. Spiny hyperkeratotic projections on the face and extremities of a kidney transplant recipient--quiz case. *Arch Dermatol*. 2006 Dec;142(12):1643-8.

Morrissey PE, Gautam A, Yango A, Grollman AP, Esparza, A, **Gohh RY**, Monaco AP. Transplantation for Chinese Herb Nephropathy. *Clin Transpl*. 2006;:560.

Patel, CG, Harmon M, **Gohh RY**, Akhlaghi F. Concentrations of mycophenolic acid and glucuronide metabolites under concomitant therapy with cyclosporine or tacrolimus. *Ther Drug Monitor* 2007 Feb;29(1):87-95.

Gautam A, Fischer SA, Yango AF, **Gohh RY**, Morrissey PE, Monaco AP. Suppression of cell-mediated immunity by a donor-transmitted lymphocytic choriomeningitis virus in a kidney transplant recipient. *Transpl Infect Dis*. 2007 Apr 11.

Mendonca AE, Zahir H, **Gohh RY**, Akhlaghi F. Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. *Ther Drug Monit* 2007;29: 391-398.

Patel CG, Richman K, Yang DF, Yan BF, **Gohh RY**, Akhlaghi F. Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients, *Ther Drug Monit*. 2007 Dec;29(6):735-742.

Phillips B, Gopalakrishnan G, **Gohh R**, Hennessey J. A case of lithium toxicity associated with profound hypothyroidism. *Thyroid*. 2008 Jun;18(6):651-4.

Mendonza AE, **Gohh RY**, Akhlaghi F., Blood and plasma pharmacokinetics of ciclosporin in diabetic kidney transplant recipients. *Clin Pharmacokinet*. 2008;47(11):733-42.

Aboagye-Kumi M, Fischer S, Donahue J, Morrissey P, Taylor N, Gautam A, Mendonca C, Kumar S, **Gohh R**. Acute disseminated encephalomyelitis in a renal transplant recipient: A case report. *Transplant Proc*. 2008 Jun; 40(5):1751-3.

Gong R, Ge Y, Chen S, Liang E, Esparza A, Sabo E, Yango A, **Gohh R**, Rifai A, Dworkin LD. Glycogen synthase kinase 3 β : a novel marker in chronic renal allograft disease. *Am J Transplant*. 2008 Sep;8(9): 1852-63.

Yango A, **Gohh R**, Wang LJ, Morrissey P, Shih M, Lowery K, Charpentier K, Gautam A, Mendonca C, Kumar S, Dworkin L, Monaco A. The utility of 6-month protocol biopsy under modern immunosuppression. Clin Nephrol. 2008 Dec;Volume 70(December):490-495.

Akhlaghi F, **Gohh R**. The level of ATP production in mitogen-stimulated CD4+ lymphocytes Is independent of the time of Ingestion of immunosuppressive agents. Ther Drug Monit. 2010 Feb;32(1):116-7.

Bolin P, **Gohh R**, Kandaswamy R, Shihab FS, Wiland, A, Akhlaghi F, Melancon K. Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter? Transplant Rev (Orlando). 2011 Apr 27.

Akhlaghi F, Dostalek M, Falck P, Mendonza AE, Amundsen R, **Gohh RY**, Asberg A. The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. Ther Drug Monit. 2012 Feb;34(1):38-45.

Gurin L, **Gohh R**, Evangelista P. Pain syndrome with stress fractures in transplanted patients treated with calcineurin inhibitors. Clin Kidney J 2012; 0: 1-4. [Epub ahead of print]

Akhlaghi F, Dostalek M, Falck P, Mendonza A, Amundsen R, **Gohh RY**, Åsberg. A.The Concentration of Cyclosporine Metabolites is Significantly Lower in Kidney Transplant Recipients with Diabetes Mellitus. Ther Drug Monit. 2012 Feb;34(1):38-45.

OTHER PEER-REVIEWED PUBLICATIONS

Bostom AG, Shemin D, **Gohh RY**, Beaulieu AJ, Bagley P, Massy ZA, Jacques PF, Dworkin L, Selhub J. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients. Kidney Int 2001; 59 (supp 78): S246-S252.

Ryder BA, **Gohh RY**, Hopkins B, Yango A, Morrissey PE. Sensitization in renal transplantation. Surgical Rounds 2004; 27(9): 422-27.

Capaldi L, Robinson-Bostom L, Kerr P, **Gohh R**. Localized cutaneous post-transplant EBV associated lymphoproliferative disorder. J Am Acad Dermatol. 2004 Nov;51(5 Suppl):778-80.

BOOKS AND BOOK CHAPTERS

Morrissey PE, **Gohh RY**, Monaco AP. Allorecognition and tissue typing in organ transplantation. In: Immunology for Surgeons. Zbar AP, Guillou PJ, Bland KI, Syrigos KN, eds., Springer-Verlag, London UK, 2002.

OTHER NON-PEER REVIEWED PUBLICATIONS

Chazan JA, **Gohh RY**. When and how should vitamin D be used in dialysis patients? *Sem in Dialysis* 1995; 85: 87.

Endreny R, **Gohh RY**. Acute obstructive nephropathy. *Hospital Practice* 1998; 33(8): 76.

Bostom AG, **Gohh RY**, Morrissey P. Hyperhomocysteinemia in chronic renal transplant recipients. *Graft* 2000; 3(4): 29.

Morrissey PE, Madras PN, **Gohh RY**, Monaco AP. Laparoscopic versus open donor nephrectomy. *Kidney Int* 2000; 58(6): 2596.

Gohh RY, Yango A, Morrissey P. The altruistic living donor: a commentary and two questions (letter). *Nephrol Dial Transplant* 2001; 16(10): 2109-2110.

Gohh RY, Yango AF. The evolution of transplantation on Rhode Island. *Medicine and Health/RI* 2002; 85(4): 116-117.

Thursby MA, Yango AF, **Gohh RY**. An update in transplant immunosuppressive therapy. *Medicine and Health/RI* 2002; 85(4): 130-132.

Gohh R. Chronic Kidney Disease, Dialysis, and Transplantation: Companion to Brenner and Rector's *The Kidney* (Book Review). *Transplantation*. 81(11):1607, June 15, 2006.

Gohh RY, Warren G. The Preoperative Evaluation of the Transplanted Patient for Nontransplant Surgery. *Surg Clin N Am* 2006; 86: 1147-1166.

Lowery KM, **Gohh RY**. Considerations for the Inpatient Care of Solid Organ Recipients. *Medicine and Health/RI* 2007; 90 (3): 84-86.

Gohh RY, Shaffi SK. Long-term results of early plasmapheresis to prevent recurrence of FSGS in high-risk renal transplant recipients. *Tx Med* 2010; 22: 287-294.

CORPORATE AUTHORSHIP OR MULTICENTER TRIALS

Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF; Sirolimus High-Risk Study Group. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results of an open-label, randomized trial. *Transplantation*. 2008 Nov 15;86(9):1187-95. (site investigator)

Pescovitz MD, Nezakatgoo N, Lorber MI, Nashan B, Tedesco-Silva H Jr, Kasiske BL, de la Cruz FJ, Russ G, Campistol J, Keown PA; International Sirolimus Study Group. Prospective observations study of sirolimus as primary immunosuppression after renal transplantation. *Transplantation*. 2009 Oct 27;88(8):1010-8. (site investigator)

PUBLICATIONS SUBMITTED OR IN PREPARATION

Dostalek M, Sam WJ, Paryani KR, Macwan JS, Gohh RY, Akhlaghi F. Diabetes Mellitus Reduces the Clearance of Atorvastatin-Lactone: the Results of a Population Pharmacokinetic Analysis in Kidney Transplant Recipients and in vitro Studies Using Human Liver Microsomes. Accepted for publication, March 5, 2012, *Clinical Pharmacokinetics*.

Dostalek M, Gohh R, Akhlaghi F. Inosine monophosphate Dehydrogenase expression and activity is markedly lower in kidney transplant recipients with diabetes mellitus. Submitted for publication, Nov 14, 2011, *British Journal of Pharmacology*

Chitnis SD, Ogasawara K, Moll V, Schniedewind B, Gohh RY, Christians U, Akhlaghi F. Effect of diabetes mellitus and cytochrome P4503A gene polymorphism on the concentration of tarolimus and major metabolites. Submitted for publication, February 21, 2012.

Richman K, Gohh R. Pregnancy after Renal Transplantation: A Review of Registry and Single-Center Practices and Outcomes. Submitted for publication, May 23, 2012, *Clinical Kidney Journal*.

ABSTRACTS

Shemin D, **Gohh RY**, Dworkin LD, Bostom AG, Wilson PW, Hartman W, Prior R, Selhub J. Prevalence and determinants of hyperhomocysteinemia in chronic renal failure. *J Am Soc Nephrol* 1994; 5: 503.

Shemin D, **Gohh RY**, Bostom AG. Determinants of hyperhomocysteinemia in chronic renal failure treated with peritoneal dialysis. *Perit Dial Int* 1995; 15(s1): s61.

Bostom AG, **Gohh RY**, Beaulieu A, Nadeau MR, Hume AL, Jacques PF, Selhub J, Rosenberg IH. Homocysteine-lowering treatment of renal transplant recipients. *J Am Soc Nephrol* 1997.

Bostom AG, **Gohh RY**, Lapane KL, Jacques PF, Dworkin LD, Rosenberg IH, Selhub J. Divergent impact of folic acid fortification of cereal grain flour on the prevalence of mild fasting hyperhomocysteinemia in renal transplant versus coronary artery disease patients. *J Am Soc Nephrol* 1998; 9: 667A.

Hakas D, **Gohh RY**, Bausserman L, Jacques PF, Dworkin L, Rosenberg IH, Selhub J, Bostom AG. Serum cystatin C, a sensitive indicator of glomerular filtration rate, independently predicts fasting

total homocysteine levels in stable renal transplant recipients with normal serum creatinine. *J Am Soc Nephrol* 1998; 9: 668A.

Morrissey PE, **Gohh RY**, Centracchio J, Madras PN, Monaco AP, Dworkin LD. Hepatocyte growth factor becomes elevated after donor nephrectomy and renal transplantation. American Society of Transplantation, 19th Annual Scientific Meeting 1999, Chicago, IL.

Beaulieu AJ, Han H, **Gohh RY**, Monaco AP, Jacques PF, Rosenberg IH, Selhub J, Bostom AG. Homocysteine levels in renal transplantation: Determinants in the era of folic acid fortified flour. American Society of Transplantation, 19th Annual Scientific Meeting 1999, Chicago, IL.

Han H, Beaulieu AJ, Dwyer JT, **Gohh RY**, Jacques PF, Selhub J, Meyer K, Kim YS, Park JY, Bank BK, Bostom AG. Comparison of total homocysteine levels in Korean and US renal transplant recipients. *J Am Soc Nephrol* 1999; 10: 731A.

Gohh RY, Beaulieu AJ, Han H, Hakas D, Jacques PF, Selhub J, Bostom AG. B12, but not folate status, is an independent determinant of fasting total homocysteine levels in renal transplant recipients 50 years of age and older. *J Am Soc Nephrol* 1999; 10: 730A.

Garber CE, Bostom AG, Hall JP, Monaco AP, Stearns WH, **Gohh RY**. Exercise tolerance is significantly reduced in renal transplant recipients. American Society of Transplantation, 20th Annual Scientific Meeting, Chicago 2000, IL.

Morrissey PE, **Gohh RY**, Madras PN, Monaco AP. Safety and economic advantage of routine ketoconazole use in live donor renal transplantation. American Society of Transplantation, 20th Annual Scientific Meeting 2000, Chicago, IL.

Yango A, **Gohh R**, Morrissey P, Centracchio J, Dworkin L. Renal production of hepatocyte growth factor increases after unilateral nephrectomy in man. American Society of Nephrology, 33rd Annual Meeting 2000, Toronto, Ont.

Morrissey PE, Yango A, **Gohh RY**, Monaco AP. Donor transmitted infection (DTI) after cadaver kidney transplantation. American Society of Transplantation, 21st Annual Scientific Meeting 2001, Chicago, IL.

Yango A, Zanabli A, Morrissey P, Roy A, **Gohh R**. A comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. American Society of Transplantation, 21st Annual Scientific Meeting 2001, Chicago, IL.

Bostom AG, Sunder-Plassmann G, Fodinger M, **Gohh RY**, Selhub J. Cyclosporine A use is not independently associated with increased plasma homocysteine levels in Austria or US chronic renal transplant recipients. American Society of Transplantation, 21st Annual Scientific meeting 2001, Chicago, IL.

Roy A, **Gohh RY**, Morrissey PE. Malignant nephrosclerosis as a complication of 'en bloc' renal transplantation. National Kidney Foundation Clinical Nephrology Meetings 2001, Orlando FL.

Roy A, **Gohh RY**, Morrissey PE. Plasmapheresis in post-transplant recurrence of focal segmental glomerulosclerosis in adults—decline in proteinuria predicts outcome. National Kidney Foundation Clinical Nephrology Meetings 2001, Orlando FL.

Kim E, **Gohh R**, Simpson M, Monaco A, Morrissey P. Rapid steroid withdrawal versus standard steroid treatment in patients treated with Basiliximab, Cyclosporine, and Mycophenolate Mofetil for the prevention of acute rejection in kidney transplantation: a two-year follow-up. American Society of Transplantation, 22nd Annual Scientific Meeting 2002, Washington, DC.

Morrissey PE, **Gohh RY**, Yango AF, Kestin A, Gautam A, Monaco AP. Anticoagulation permits successful renal transplantation in patients with antiphospholipid antibody syndrome (APAS). American Society of Transplantation, 22nd Annual Scientific Meeting 2002, Washington, DC.

Gohh R, Fischer S, Morrissey P, Gautam A, Monaco A, Yango A, Akhlaghi F. The pharmacologic interaction between anti-retroviral agents and tacrolimus. Abdominal Organ Transplantation from Living Donors: State of the Art, Gubbio, Italy, 2002.

Fischer SA, Murphy M, Yango A, **Gohh R**. Oerskovia endocarditis in a renal transplant recipient. Infectious Disease Society of America, 40th Annual Meeting 2002, Chicago, IL.

Gohh R, Yango A, Morrissey P, Gautam A, Monaco A. Pre-emptive plasmapheresis to prevent recurrence of focal segmental glomerulosclerosis in high-risk renal transplant recipients. World Congress of Nephrology 2003, Berlin, Germany.

Morrissey PE, **Gohh R**, Yango A, Gautam A, Hopkins B, Goguen J, Delmonical FL, Monaco AP. Decreased waiting time for cadaver renal transplantation at a single center: effect of non-traditional donors. American Transplant Congress 2003, Washington, D.C.

Akhlaghi F, **Gohh RY**, Patel CG, Zuniga P, Lin S, Yango A. Unbound but not total concentration of mycophenolic acid (MPA) is higher in diabetic kidney transplant recipients. American Transplant Congress 2004, Boston MA.

Yango A, **Gohh R**, Monaco A, Gautam A, Dworkin L, Morrissey P. Excess risk of renal allograft loss and early mortality among elderly renal transplant recipients associated with poor exercise capacity. XX International Congress of the Transplantation Society 2004, Vienna, Austria.

Lin S, Morrissey P, Gautam A, Yango A, **Gohh R**, Tacroilimus vs. cyclosporine microemulsion-based immunosuppression: equal efficacy with reduced steroid exposure. American Society of Transplant Surgeons State of the Art Winter Symposium 2004, Miami, FL.

Zahir H, Mendonza AE, Zuniga XP, **Gohh RY**, Akhlaghi F. Comparative Pharmacokinetics of cyclosporine and tacrolimus in diabetic and nondiabetic kidney transplant recipients. 3rd International Congress on Immunosuppression, 2004.

Halilovic D, Zuniga XP, **Gohh RY**, Akhlaghi F. Use of acetaminophen absorption method in characterizing delayed gastric emptying time in diabetic kidney transplant recipients. 3rd International Congress on Immunosuppression, 2004..

Akhlaghi F, Patel CG, **Gohh RY**. The effect of calcineurin inhibitors cyclosporine and tacrolimus on the pharmacokinetics of mycophenolic acid and its acyl and phenol glucuronide metabolites. American Transplant Congress 2005, Seattle, Wa.

Mendonza AE, **Gohh RY**, Zuniga XP, Akhlaghi F. Pharmacokinetics of cyclosporine in diabetic kidney transplant recipients and its correlation with acetaminophen absorption. American Transplant Congress 2005, Seattle, Wa.

Absorption, distribution and metabolism of mycophenolate mofetil (MMF) in diabetic kidney transplant recipients. American Society of Nephrology 2005, Philadelphia, Pa.

Mendonza A, Akhlaghi F, Steffes M, **Gohh R**. Determination of mycophenolic acid (MPA) in saliva using liquid chromatography tandem mass spectrometry (LC-MS/MS). AAPS Annual Meeting 2005, Nashville, TN.

Patel C, **Gohh R**, Akhlaghi F. The effect of cyclosporine vs. tacrolimus on the pharmacokinetics of mycophenolic acid and its metabolites: the possible influence of ketoconazole co-administration. AAPS Annual Meeting 2005, Nashville, TN.

Akhlaghi F, Patel C, Zuniga P, **Gohh R**. Pharmacokinetics of mycophenolic acid in diabetic kidney transplant patients. AAPS Annual Meeting 2005, Nashville, TN.

Akhlaghi F, Patel CG, Richman K, **Gohh RY**. Pharmacodynamics (PD) but not the pharmacokinetics (PK) of mycophenolic acid is altered by diabetes. World Transplant Congress 2006, Boston, Ma.

Akhlaghi F, Mendonza AE, Richman K, Zuniga P, **Gohh RY**. Diabetes mellitus affects pharmacokinetics of cyclosporine but not tacrolimus. World Transplant Congress 2006, Boston, Ma.

Gautam A, Fischer S, Gohh RY, **Gohh RY**, Yango AY, Monaco AP, Morrissey PE. Monitoring cell mediated immunity during immunosuppression for serious infection. World Transplant Congress 2006, Boston, Ma.

Gautam, Fischer SA, Yango AF, **Gohh RY**, Morrissey PE, Monaco AP. Severe suppression of cell-mediated immunity by donor transmitted lymphocytic choriomeningitis virus in kidney

transplantation recipients. World Transplant Congress, 2006, Boston, Ma.

Morrissey PE, Gautam A, Fischer SA, **Gohh RY**, Yango AF, Monaco AP. An in vitro immune cell function assay is superior to clinical judgement of overall immunosuppression. World Transplant Congress 2006, Boston, MA.

Warren GA, Wang LJ, Morrissey P, Yango A, **Gohh R**. Implantation living donor kidney biopsy findings and their relationship to donor characteristics. American Society of Nephrology, 39th Annual Meeting 2006, San Diego, CA.

Lowery K, Morrissey P, Gautam A, Monaco A, Cosgrove C, Wang L, Yango A, **Gohh R**. Living kidney donor age and kidney biopsy findings do not predict donor renal function outcomes. American Transplant Congress 2007, San Francisco, CA.

Akhlaghi F, Mendonza AE, Caldarusa, M, **Gohh RY**. Diabetic kidney transplant recipients exhibit reduced biomarkers of T- and B-cell activity. American Transplant Congress 2007, San Francisco, CA.

B D. Midkiff, D E. Dupuy, **R.Y. Gohh**, W. W. Mayo-Smith. Cost-Effectiveness of Percutaneous Radiofrequency Ablation for Malignant Primary Renal Neoplasms. 2007 Joint Annual Meeting of the World Conference on Interventional Oncology & the Society for Thermal Medicine, Washington, D.C.

B.D. Midkiff, D. Dupuy, **R.Y. Gohh**, W. Mayo-Smith. Cost-Effectiveness of Percutaneous Radiofrequency Ablation for Malignant Primary Renal Neoplasms. 2007 Annual Meeting of the Radiological Society of Nephrology, Chicago, Ill.

Tan TW, Morrissey PE, **Gohh RY**, Yango A, Charpentier KP, Monaco AP. One year outcomes following liver donor nephrectomy in high-risk donors. American Transplant Congress 2008, Toronto, Ontario

Alloway RR, Germain M, Gaber AO, Mulganokar SP, **Gohh RY**, Kaplan B, Katz E, Gordon RD. A phase II, open-label, multi-center prospective, conversion study in stable transplant patients to compare the pharmacokinetics of LCP-tacro tablets once-a-day to Prograf capsules twice-a-day. American Transplant Congress 2008, Toronto, Ontario.

Go S, **Gohh R**, Monaco A, Charpentier K, Morrissey P, Machan J, Yango A. Post-transplant anemia at six months increases the risk of graft loss and mortality among kidney transplant patients. American Transplant Congress 2008, Toronto, Ontario.

Garber CE, Nelson B, Yango AF, Morrissey PE, Charpentier K, **Gohh RY**. Physical function in patients awaiting renal transplantation. American Transplant Congress 2008, Toronto, Ontario.

Paryani K, **Gohh R**, Akhlaghi F. Elevated atorvastatin lactone concentration in patients with diabetes mellitus; Poster presentation at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 110th Annual Meeting, Washington, DC, March 18-21, 2009; Abstract published at Clinical Pharmacology and Therapeutics, volume 85 supplement 1, page S36 (2009)

Chiu R, Machan J, **Gohh R**, Fischer S, Charpentier K, Morrissey P, Monaco A, Yango A. Death after graft failure: a single center experience. American Transplant Congress, 2009. Boston, MA.

Akhlaghi F, Chitnis SR, Mendonza AE, Ionita IA, **Gohh R**. Reduced level of biomarkers of immunosuppressive activity in diabetic kidney transplant recipients is related to diabetic type and glucose control. American Transplant Congress, 2010. San Diego, CA.

Akhlaghi F, Chitnis SD, Mendonza AE, Ionita IA, **Gohh RY**. Utilization of B- and T- cell activity markers to evaluate the degree of immunosuppression in diabetic kidney transplant recipients. Poster presented at "Pharmacodynamic and Pharmacogenomic Biomarkers in Solid Organ Transplantation", Sept. 28,2010; Food and Drug Administration, White Oak Campus.

Beck LH, Cosio FG, Fervenza FC, Malik F, Francis JM, Henderson JM, Asch WM, **Gohh RY**, Salant, DJ. Anti-PLA₂R Autoantibodies in Recurrent Membranous Nephropathy. American Society of Nephrology 43rd Annual Meeting 2010, Philadelphia, PA.

Norris DC, **Gohh RY**, Akhlaghi F, Morrissey PE. Kalman Filtering for Tacrolimus Dose Titration in the Early Hospital Course after Kidney Transplant. American Transplant Congress 2011, Philadelphia, PA.

Hu S, Igari, M, **Gohh RY**. Renal Transplant Donor Glomerular Filtration Rate Determination by Plasma Clearance of Iohexol during Computed Tomographic Angiography of the Kidneys. American Transplant Congress 2012, Boston, MA.

SCHOLARLY WORK PUBLISHED IN OTHER MEDIA

Gohh RY, Morrissey PE. Altruistic living donors: exploring the option. 3rd Congress of Nephrology in Internet (CIN'2003).

Yango AF, **Gohh RY**. Update in the management of highly sensitized patients. 5th Congress of Nephrology in Internet (CIN '2009)

INVITED PRESENTATIONS

1. American College of Physicians, Rhode Island Annual Meeting, May 1993. "Acute Renal Failure in Waldenstrom's Macroglobulinemia."

2. American Society of Peritoneal Dialysis, Annual Scientific Meeting, St. Louis, Mo, May 1995. "Hyperhomocysteinemia in Peritoneal Dialysis Patients."
3. American Society of Transplant Physicians Annual Scientific Meeting, May 1997, Chicago, IL. "Excess Prevalence of Fasting and Post-methionine Loading Hyperhomocysteinemia in Stable Renal Transplant Patients."
4. Medical Grand Rounds, Rhode Island Hospital, Providence, RI, October 1998, "Medical Complications of Renal Transplantation"
5. Medical Grand Rounds, Rhode Island Hospital, Providence, RI, September 1999, "Living-Unrelated Renal Transplantation."
6. Renal Grand Rounds, Rhode Island Hospital, Providence, RI, May 2002, "Recurrent FSGS Following Kidney Transplantation"
7. Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, March 2003, "Pulmonary-Renal Syndrome"
8. Rhode Island Diabetes and Endocrine Society, Providence, RI, November 2003, "Medical Outcomes of Pancreas Transplantation"
9. Rheumatology Grand Rounds, Roger Williams Hospital, Providence, RI, March 2004, "Renal Transplantation for Autoimmune Disease"
10. Medicine Grand Rounds, Roger Williams Hospital, Providence, RI, April 2006, "Focal Segmental Glomerulosclerosis and its Post-transplant Recurrence"
11. Transplant Grand Rounds, Beth Israel/Deaconess Hospital, Providence, RI, June 2006, "Recurrent FSGS in the Renal Transplant Recipient"
12. National Institute of Transplantation of Paraguay, Asuncion, Paraguay, August 2006, "Organ Donation"
13. Renal Grand Rounds, Jin Ling Hospital, Nanjing, China, August 2008, "Update In Recurrent FSGS in the Renal Transplant Recipient"
14. Nephrology for Practicing Clinicians- A Current Approach, Joslin Diabetes Center, Boston, MA, September 2010, "Acute and Chronic Rejection"
15. Nephrology for Practicing Clinicians- A Current Approach, Harvard Medical School, Boston, MA, May 2011, "Acute and Chronic Rejection"
16. Urology Grand Rounds, Rhode Island Hospital, Providence, RI, September 2011, "Renal Physiology and Pathophysiology for the Urologist"
17. Morbidity and Mortality Conference, Rhode Island Hospital, Providence, RI, October 2011, "A 64-year-old female with right hip and thigh pain "
18. Nephrology for Practicing Clinicians—A Current Approach, Harvard Medical School, Boston, Ma, May 2012, "Acute and Chronic Rejection"

GRANTS

“Folic acid treatment to reduce fasting plasma total homocysteine levels in renal transplant recipients: a dose-finding study.” Principal Investigator. Study sponsored by the National Kidney Foundation, 1998-1999, \$15,000, 7/98-6/99.

“Subclinical carotid arteriosclerosis in renal transplant recipients: association with aerobic capacity and traditional cardiovascular disease risk factors.” Principal Investigator. Study sponsored by Lifespan Developmental Grant, \$17,146.25, 3/98-2/99.

“A multicenter, randomized, open label trial of Simulect™ with rapid steroid withdrawal vs. Simulect™ with standard treatment in subjects treated with Neoral® and Cellcept® for the prevention of acute rejection in renal transplantation.” Principal Investigator. Study sponsored by Novartis Pharmaceuticals. Study No: CHI INT 12, \$21,560. 5/98-3/02.

“A phase IV epidemiologic demonstration of SangCyA™ (Cyclosporine Oral Solution, USP [Modified]) safety using a pharmacovigilance data collection system.” Principal Investigator. Study sponsored by Sangstat Pharmaceutical Corporation, \$5,000, 10/99-5/00.

“An open-label, multicenter study to further characterize the clinical utility and safety of Rapamune® and Cyclosporine combination treatment in de novo renal allograft recipients.” Principal Investigator. Study sponsored by Wyeth-Ayerst Laboratories, \$37,500, 11/99-3/02.

“A comparative, open-label study to evaluate graft function in de novo renal allograft recipients treated with either a ‘reduced dose’ or a ‘standard dose’ of Cyclosporine in combination with Rapamune® (Sirolimus) + Corticosteroids.” Principal Investigator. Study sponsored by Wyeth-Ayerst Pharmaceuticals, \$81,400, 5/00-present.

“A randomized, open-label preference study of Gengraf compared to Neoral in stable solid-organ transplant subjects.” Principal Investigator. Study sponsored by Abbott Pharmaceuticals, \$12,500, 6/00-3/02.

“Pilot study to induce specific unresponsiveness with donor specific peripheral blood mobilized bone marrow stem cells (PBSCs) in recipients of living donor, mismatched renal allografts treated with Thymoglobulin and standard cyclosporine based immunosuppression.” Co-Principal Investigator. Study sponsored by AMGEN Pharmaceutical Corporation, \$22,500, 8/00-present.

“Rapamune Outcomes Assessment Registry.” Principal Investigator. Study sponsored by Wyeth-Ayerst Pharmaceuticals, \$12,000, 10/00-present.

“Simulect induction followed by overall reduction in immunosuppression exposure after renal transplantation (SIRE).” Co-investigator. Study sponsored by Novartis Pharmaceuticals, 2001-present.

“Registry of Simulect use in living donor renal transplantation (ReSULTS).” Co-investigator. Study sponsored by Novartis Pharmaceuticals, 2001-present.

“A 1-year multicenter, randomized study of safety and tolerability and efficacy of two doses of Certican (RAD001) with steroids and optimized administration of Neoral in de novo renal transplant recipients.” Co-investigator. Study sponsored by Novartis Pharmaceuticals, 2002-present.

“A prospective, randomized, multicenter double blind study of early corticosteroid withdrawal cessation vs. long-term maintenance corticosteroid therapy with Prograf and Cellcept in primary renal transplant recipients.” Co-investigator. Study sponsored by Fujisawa Pharmaceuticals, \$15,000, 2002-present.

“A multicenter study evaluating once every other week subcutaneous administration of Aranesp (darbepoetin alfa) in subjects with anemia of chronic renal insufficiency.” Co-investigator. Study sponsored by Amgen Pharmaceuticals, \$6200, 8/02-present.

“An open-label, concentration-controlled, randomized, 12 month study of Prograf + Rapamune + Corticosteoids compared to Cyclosporine capsules, USP (modified) + Rapamune + Corticosteroids in high-risk renal allograft recipients.” Principal Investigator. Study sponsored by Wyeth-Ayerst Pharmaceuticals, \$115,900, 9/03-present.

“Evaluation of immune globulin, intravenous, human manufactured using a new chromatographic method (IgIV-C), as an agent to reduce anti-HLA antibodies and improve transplantation results in cross match positive living donor kidney allograft recipients (Protocol IgO3).” Principal Investigator. Study sponsored by the NIH, \$18,746, 6/03-3/05.

“Pharmacokinetics of mycophenolic acid in diabetes (Protocol CEL386).” Principal Investigator. Study sponsored by Roche Pharmaceuticals, \$25,721, 6/03-7/04.

“A one-year, multicenter, double-blinded, double-dummy, randomized study to evaluate the safety and efficacy of two doses of FTY720 combined with full-dose Neoral® and steroids versus Cellcept® combined with full-dose Neoral® and steroids in *de novo* renal transplant recipients. Study sponsored by Novartis Pharmaceuticals, 2004- 09/05.

“Diabetic incidence after renal transplantation: Neoral C-2 monitoring vs. Tacrolimus—A 6-month open-label multicenter, randomized control study to compare the incidence of new onset diabetes mellitus and glucose metabolism in patients receiving Neoral with C-2 monitoring vs. tacrolimus after *de novo* kidney transplantation.” Study sponsored by Novartis Pharmaceuticals, \$124,728, 9/04-present.

“A randomized, open-label study to compare the safety and efficacy of two different Rapamune regimens with a Tacrolimus and Mycophenolate Mofetil regimen in *de novo* renal allograft recipients.” Study sponsored by Wyeth-Ayerst Pharmaceuticals, \$115,618, 8/04- present.

“An open-label, prospective, randomized, controlled, multi-center study assessing fixed dose vs. concentration-controlled Cellcept regimens for patients following single organ renal transplantation in combination with full dose and reduced dose calcineurin inhibitors.” Primary Investigator. Study sponsored by Roche Laboratories, \$202,375, 10/04- present.

“Pharmacokinetics and Dynamics of Mycophenolate Sodium in Diabetes.” Primary Investigator. Study sponsored by Novartis Pharmaceuticals Corporation, \$23,526, 5/05- 3/06.

“Mycophenolic acid Observational Renal Transplant Program: A Phase IV non-interventional, multi-center, open-label, prospective, observational study of the safety, effectiveness, tolerability and compliance of immunosuppressive regimens using mycophenolic acid to treat *de novo* renal transplant patients in routine practice (Protocol CERL080US40).” Primary Investigator. Study sponsored by Novartis Pharmaceuticals, \$28,112, 8/07 – 6/12.

“A Phase 2 Open-label, multi-center prospective conversion study in stable kidney transplant patients comparing the pharmacokinetics of LCP-Tacro tablets once-a-day”. Primary Investigator. Study sponsored by Lifecycle Pharma, \$66,396, 9/20/07-

“A randomized, placebo controlled, double-blind comparative study evaluation the effect of ramipril on urinary protein excretion in maintenance renal transplant recipients converted to sirolimus”. Primary Investigator. Study sponsored by Wyeth Pharmaceuticals, \$140,900, 3/08-present.

“A phase 3, open-label, multicenter, prospective, randomized study of the efficacy and safety of conversion from Prograf capsules twice daily to LCP-Tacro once daily for the prevention of acute

allograft rejection in stable kidney transplant patients. Primary Investigator. Study sponsored by Lifecycle Pharma, 2011.

“Novel oral fluid based methods for non-invasive determination of total exposure to active immunosuppressive agents”. Primary Investigator. Study sponsored by Rhode Island Research Alliance Grant, \$31,668, 3/10-3/11.

“Smart pill technology for the exact evaluation of gastrointestinal residence time in diabetic kidney transplant recipients after conversion to EC-MPS/.” Primary Investigator. Study Sponsored by Novartis Pharmaceuticals, Study # CERL080A- US82T, \$52,650, 1/10- 1/11.

“A phase 3, double-blind, double-dummy, multi-center, prospective, randomized study of the efficacy and safety of LCP-Tacro™ tablets, once daily, compared to Prograf® capsules, twice daily, in combination with Mycophenolate Mofetil for the prevention of acute allograft rejection in de novo adult kidney transplant recipients.” Primary Investigator. Study sponsored by Lifecycle Pharma, protocol no. LCP-Tacro 3002. \$171,530. 2/1/2011 – present.

“Pharmacokinetics and Dynamics of Sirolimus in Diabetic Kidney Transplant Recipients.” Primary Investigator. Study sponsored by Pfizer Pharmaceuticals, 12/17/10

“Reduction of Proteinuria with Selective Vitamin D Receptor Activation using Paricalcitol in Renal Transplant Patients.” Primary Investigator. Study sponsored by Abbott Pharmaceuticals, 4/7/11.

“A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 days of Valganciclovir vs. Concurrent Untreated Matched Controls. Primary Investigator. Study sponsored by Genentech/Covance, Protocol No. WV25651, \$28,360, 1/20/12.

UNIVERSITY TEACHING ROLES:

1992-1993	Medical Interviewing
1995-present	Renal Pathophysiology (Biomed 281) -Lecturer, small group leader
1995-2000	Physical Diagnosis
2000-2001	Immunology (MMI), Professor Walter Atwood -Lecturer
2001-present	Longitudinal Clinic Preceptor -Katherine Richman (BMS, 2003) -Barrett Bready (BMS, 2003) -Nora Taylor (PGY II) -George Bayliss (PGY III) -Kristel Jernigan (PGY II,III) -Fahmeedah Jamaluddin (PGY II) -David DeWolf (PGY II)
2004	Summer Research Preceptor -Ido Preis (BMS, 2007)

HOSPITAL TEACHING ROLES:

- | | |
|--------------|--|
| 1995-present | Teaching medical residents and fellows in various settings (morning report, lecturing at noon conferences) |
| 1995-present | Transplant/Nephrology Elective teaching attending for renal fellows, medical residents and students |
| 1997-present | Transplant Grand Rounds- organizer (monthly) |
| 1998-present | Medical resident and student rotator conference (renal pathophysiology lecture series for students and residents taking renal elective)- organizer (weekly) |
| 1999-present | Medical inpatient teaching attending for inpatient ward team(s)- one to two months a year |
| 1999-2000 | Fellowship Director, Renal Transplant Fellowship (one year fellowship)- one fellow per year
-Angelito Yango (2000) |